The acquired technology covers the use of RNA Inte

The acquired technology covers the use of RNA Interference to specifically inhibit the enzyme indolamine 2,3 deoxygenase (IDO). Tumors are known to escape the immune system by specifically activating this enzyme. In the patent and previous publication, Dr. Min and his team demonstrated that by blocking function of IDO, tumors would enter remission.

"My laboratory is looking forward to working with Bio-Matrix Scientific's Regen BioPharma towards advancing our new method of treating cancer from mice to people,"stated Dr. Wei-Ping Min, Professor at the University of Western Ontario."Having previously published(3) with Dr. Koos on our RNA interference technique, I am eager to now expand our collaboration into the area of oncology."